ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Adaptive Biotechnologies Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$23.95−0.07 (-0.29%)
Close on Oct 19, 2026
- Market cap
- $3.83B
- P/E (TTM)
- –
- Dividend yield
- –
Adaptive Biotechnologies Corp revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q4 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRD | $251.94M | $235.71M | $212.33M | $190.60M | $171.28M | $156.62M | $145.53M | $136.14M | $123.34M | $113.94M | $102.74M | – | 81.8% | +47.1% |
| Immune Medicine | $56.15M | $59.70M | $64.64M | $62.16M | $33.94M | $32.90M | $33.43M | $41.14M | $45.43M | $60.56M | $67.54M | – | 18.2% | +65.4% |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q4 21 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Development Revenue | – | – | – | – | – | – | – | – | – | – | – | $75.45M | – | – |
| Sequencing Revenue | – | – | – | – | – | – | – | – | – | – | – | $78.90M | – | – |
| Immune Medicine Service Revenue | – | – | $41.30M | $44.70M | $14.50M | $12.40M | $13.50M | $17.90M | $22.40M | $38.10M | $42.60M | – | – | – |
By region
From the segment and revenue-disaggregation notes of Adaptive Biotechnologies's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.